Skin Infections, Bacterial Clinical Trial
Official title:
A Study to Evaluate the Feasibility of Microdialysis to Determine Skin Concentrations of Retapamulin in Healthy Volunteers
This feasibility study will allow for the determination of the in vivo recovery and time of dialysis to optimize a future thorough microdialysis study. This is a single session, open label study to evaluate the feasibility of microdialysis for Retapamulin in healthy subjects. Three healthy subjects will be enrolled and complete the study procedures. Subjects will be admitted to the research unit on Day 1 and three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure. After normal saline solution infusion for 30 minutes, a Retapamulin solution will be infused for 90 minutes. Saline perfusion will occur during the washout period. Microdialysis sampling will be done for 30 minutes (during the last 30 minutes of drug perfusion) and dialysate sample collection will continue every 30 minutes for 4 hours. The approximate duration of study including follow-up is 4 days.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00555061 -
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
|
Phase 4 | |
| Completed |
NCT01445600 -
ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
|
N/A | |
| Completed |
NCT00684177 -
Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
|
Phase 3 | |
| Completed |
NCT01153880 -
United States Pharmacovigilence Retapamulin-Prescribing
|
N/A | |
| Completed |
NCT01209078 -
GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
|
Phase 2 | |
| Completed |
NCT00852540 -
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
|
Phase 3 | |
| Completed |
NCT00133874 -
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
|
Phase 3 |